Evidence map›Paper›PMID 40902993›Full record

ArticleClinical nuclear medicine2025

MetaPredictomics: A Comprehensive Approach to Predict Postsurgical Non-Small Cell Lung Cancer Recurrence Using Clinicopathologic, Radiomics, and Organomics Data.

Mehdi Amini, Ghasem Hajianfar, Yazdan Salimi, Zahra Mansouri, Habib Zaidi

Abstract read
In one paragraph

Article in Clinical nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Advances on Postoperative Recurrence Risk Prediction in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehdi AminiDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0002-4370-680
Ghasem HajianfarDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0001-5359-2407
Yazdan SalimiDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0002-1233-9576
Zahra MansouriDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0003-2087-9721
Habib ZaidiDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0001-7559-5297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is a complex disease characterized by diverse clinical, genetic, and histopathologic traits, necessitating personalized treatment approaches. While numerous biomarkers have been introduced for NSCLC prognostication, no single source of information can provide a comprehensive understanding of the disease. However, integrating biomarkers from multiple sources may offer a holistic view of the disease, enabling more accurate predictions. In this study, we present MetaPredictomics, a framework that integrates clinicopathologic data with PET/CT radiomics from the primary tumor and presumed healthy organs (referred to as "organomics") to predict postsurgical recurrence. PATIENTS AND

methodsA fully automated deep learning-based segmentation model was employed to delineate 19 affected (whole lung and the affected lobe) and presumed healthy organs from CT images of the presurgical PET/CT scans of 145 NSCLC patients sourced from a publicly available data set. Using PyRadiomics, 214 features (107 from CT, 107 from PET) were extracted from the gross tumor volume (GTV) and each segmented organ. In addition, a clinicopathologic feature set was constructed, incorporating clinical characteristics, histopathologic data, gene mutation status, conventional PET imaging biomarkers, and patients' treatment history. GTV Radiomics, each of the organomics, and the clinicopathologic feature sets were each fed to a time-to-event prediction machine, based on glmboost, to establish first-level models. The risk scores obtained from the first-level models were then used as inputs for meta models developed using a stacked ensemble approach. Questing optimized performance, we assessed meta models established upon all combinations of first-level models with concordance index (C-index) ≥0.6. The performance of all the models was evaluated using the average C-index across a unique 3-fold cross-validation scheme for fair comparison.

resultsThe clinicopathologic model outperformed other first-level models with a C-index of 0.67, followed closely by GTV radiomics model with C-index of 0.65. Among the organomics models, whole-lung and aorta models achieved top performance with a C-index of 0.65, while 12 organomics models achieved C-indices of ≥0.6. Meta models significantly outperformed the first-level models with the top 100 achieving C-indices between 0.703 and 0.731. The clinicopathologic, whole lung, esophagus, pancreas, and GTV models were the most frequently present models in the top 100 meta models with frequencies of 98, 71, 69, 62, and 61, respectively.

conclusionsIn this study, we highlighted the value of maximizing the use of medical imaging for NSCLC recurrence prognostication by incorporating data from various organs, rather than focusing solely on the tumor and its immediate surroundings. This multisource integration proved particularly beneficial in the meta models, where combining clinicopathologic data with tumor radiomics and organomics models significantly enhanced recurrence prediction.

Indexed as

Carcinoma, Non-Small-Cell LungImage Processing, Computer-AssistedLung NeoplasmsNeoplasm Recurrence, LocalAgedFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadiomicsdeep learningnon–small cell lung cancerorganomicsPET/CTradiomics

Identifiers

PMID40902993
PMCPMC12617314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.